Developing new antifungal treatments targeting a specific fungal enzyme
Targeting fungal ceramide synthases as new antifungals
['FUNDING_OTHER'] · MICRORID TECHNOLOGIES, INC. · NIH-11003526
This study is looking for new and better antifungal medicines by targeting a specific enzyme that helps harmful fungi survive, which could lead to improved treatments for serious infections like cryptococcosis, candidiasis, and aspergillosis.
Quick facts
| Phase | ['FUNDING_OTHER'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | MICRORID TECHNOLOGIES, INC. (nih funded) |
| Locations | 1 site (DIX HILLS, UNITED STATES) |
| Trial ID | NIH-11003526 on ClinicalTrials.gov |
What this research studies
This research aims to create more effective antifungal medications by targeting a specific enzyme called ceramide synthase 1, which is crucial for the survival of certain harmful fungi. The researchers will screen a library of compounds to find those that can inhibit this enzyme, potentially leading to new treatments for serious fungal infections like cryptococcosis, candidiasis, and aspergillosis. By focusing on a unique aspect of fungal biology, the goal is to develop therapies that are more potent and selective than existing antifungals, which could improve patient outcomes significantly.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals suffering from invasive fungal infections, particularly those caused by cryptococcosis, candidiasis, or aspergillosis.
Not a fit: Patients with non-invasive fungal infections or those not affected by the specific fungi targeted in this research may not benefit.
Why it matters
Potential benefit: If successful, this research could lead to the development of new antifungal drugs that are more effective against life-threatening fungal infections.
How similar studies have performed: While targeting fungal ceramide synthases is a novel approach, previous research has shown promise in developing antifungals by focusing on specific fungal enzymes.
Where this research is happening
DIX HILLS, UNITED STATES
- MICRORID TECHNOLOGIES, INC. — DIX HILLS, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: DEL POETA, MAURIZIO — MICRORID TECHNOLOGIES, INC.
- Study coordinator: DEL POETA, MAURIZIO
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Acquired Immune Deficiency Syndrome, Acquired Immunodeficiency Syndrome